Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Gastrointestinal (Noncolorectal) Cancer

Type: Poster Session

Time: Monday June 3, 8:00 AM to 11:00 AM

Location: Hall A

Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).

Sub-category:
Hepatobiliary Cancer

Category:
Gastrointestinal (Noncolorectal) Cancer

Meeting:
2019 ASCO Annual Meeting

Abstract No:
4087

Poster Board Number:
Poster Session (Board #192)

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 4087)

Author(s): Milind M. Javle, Karthikeyan Murugesan, Rachna T. Shroff, Mitesh J. Borad, Reham Abdel-Wahab, Alexa Betzig Schrock, Jon Chung, Lipika Goyal, Garrett M. Frampton, Robin Kate Kelley, Vincent A. Miller, Jeffrey S. Ross, Tanios S. Bekaii-Saab, Siraj Mahamed Ali, Lee A. Albacker; University of Texas MD Anderson Cancer Center, Houston, TX; Foundation Medicine, Inc., Cambridge, MA; The University of Texas MD Anderson Cancer Center, Houston, TX; Mayo Clinic Cancer Center, Scottsdale, AZ; Assiut University Hospital, Faculty of Medicine, Assiut, Egypt; Massachusetts General Hospital, Boston, MA; University of California San Francisco, San Francisco, CA; SUNY Upstate Medical University, Syracuse, NY; Mayo Clinic, Phoenix, AZ

Abstract Disclosures

Abstract:

Background: The management of CCA has evolved as targeted and immune checkpoint inhibitor (ICPI) therapies have emerged. We used comprehensive genomic profiling (CGP) to characterize the genomic alterations (GA) that have potential to personalize therapy for CCA. Methods: 3634 CCA underwent hybrid capture based CGP on 0.8-1.1 Mb of the coding genome to identify GAs in exons and select introns in up to 404 genes, TMB, microsatellite status (MSI) and % monoallelic genome (gLOH). PD-L1 expression was determined by IHC (Dako 22C3). Results: 52% of CCA were female with a median age of 62 years (range 16 - > 89). The most common biopsy sites were liver (74%), lymph node (4%), bile duct (3.3%), and lung (2%). MSI-high was rare (1%), 118 and 47 cases had TMB > 10 and > 20 mut/mb respectively. Of the latter, 51% (24/47) were MSI-H. PD-L1 amplification (AMP) was present in 0.27%. Of 490 CCA tested, 43 (9%) were positive for PD-L1 expression. 11% of cases had gLOH > 16%, only 2 cases had both TMB > 20 and gLOH > 16%. GA were most common in TP53 (31%), CDKN2A (29%), KRAS (20%) and ARID1A (17%). Potentially targetable GAs included FGFR2 (11%, 85% fusions), BRAF (5%, 50% V600E), ERBB2 (5%, 72% AMP), MET (2%, 90% AMP), EGFR (0.52%) and rarer ( < 0.5%) FGFR3, RET, FGFR1, ALK, and ROS1 fusions. The FGFR2 fusions had 128 unique 3’ partner genes including BICC1 (26%), CCDC6 (3.2%), AHCYL1 (2.6%) and KIAA1217 (2.6%). FGFR2 fusions occurred in a mutually exclusive fashion from high gLOH (p < 0.002), but not high TMB. GA in IDH1 (15%) were mutually exclusive of FGFR2 fusions (p < 1e-13), but co-occurred with PBRM1 GA (23%, p < 1e-21), ARID1A (26% p < 1e-10). IDH1 GA had gLOH similar to the overall CCA population but were enriched for low TMB (p < 1e-3). Conclusions: Nearly 20% of CCA cases harbor targetable kinase GA, half of which were FGFR2 fusions. Independently, an additional 10% (gLOH) and 1% (high TMB, MSI and/or PD-L1 AMP) may benefit from PARP inhibitors and ICPI respectively. Independently, co-mutation of IDH1 and PBRM1/ARID1A defines a class of CCA that warrants further investigation for sensitivity to PARP inhibitors and may serve as a paradigm for other tumors (ie. gliomas) with a similar co-occurrence landscape.

 
Other Abstracts in this Sub-Category:

 

1. A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial).

Meeting: 2019 ASCO Annual Meeting Abstract No: 4002 First Author: Namiki Izumi
Category: Gastrointestinal (Noncolorectal) Cancer - Hepatobiliary Cancer

 

2. ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

Meeting: 2019 ASCO Annual Meeting Abstract No: 4003 First Author: Angela Lamarca
Category: Gastrointestinal (Noncolorectal) Cancer - Hepatobiliary Cancer

 

3. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

Meeting: 2019 ASCO Annual Meeting Abstract No: 4012 First Author: Thomas Yau
Category: Gastrointestinal (Noncolorectal) Cancer - Hepatobiliary Cancer

 

More...